INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
← catalyst calendarSponsored by Incyte Corporation (industry) · INCY — their whole pipeline →.
Phase
Phase 1/2
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
84actual
Sites
34
Countries
Canada, France, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-19 | actual | When the study began enrolling |
| Primary completion | 2025-04-01 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-11-26 | estimated | The whole study's end, after follow-up |
| First posted | 2020-07-02 | actual | When this record first appeared on the registry |
| Results posted | 2026-05-12 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-05-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Anemia
- Post-essential Thrombocythemia Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
Interventions
- Drug: INCB000928
- Drug: ruxolitinib
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-emergent Serious Adverse Event (SAE)
measured up to approximately 4 years
Number of Participants With Any ≥Grade 3 TEAE and Any Treatment-emergent SAE
measured up to approximately 4 years
Number of Participants With Dose-limiting Toxicities (DLTs)
measured from Cycle 1 Day 1 to Cycle 1 Day 28
Maximum Tolerated Dose (MTD)
measured from Cycle 1 Day 1 to Cycle 1 Day 28
Recommended Dose for Expansion (RDE)
measured from Cycle 1 Day 1 to Cycle 1 Day 28
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-02-20 · 1.8 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-04-17 · 593 KB · SAP_001.pdf
Publications
- PMID 38837732 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · INCY's whole pipeline · Catalyst calendar · Every registered study · What changed